Longitudinal Racial/Ethnic Disparities in Antimanic Medication Use in Bipolar-I Disorder

Division of Alcohol and Drug Abuse, McLean Hospital, Belmont, Massachusetts 02478, USA.
Medical care (Impact Factor: 3.23). 09/2009; 47(12):1217-28. DOI: 10.1097/MLR.0b013e3181adcc4f
Source: PubMed


To examine racial/ethnic longitudinal disparities in antimanic medication use among adults with bipolar-I disorder.
Observational study using administrative data from Florida's Medicaid program, July 1997 to June 2005, for enrollees diagnosed with bipolar-I disorder (N = 13,497 persons; 126,413 person-quarters). We examined the likelihood of receiving one of the following during a given quarter: (1) any antimanic agent (antipsychotic or mood stabilizer) or none, and (2) mood stabilizers, antipsychotic monotherapy, or neither. Binary and multinomial logistic regression models predicted the association between race/ethnicity and prescription fills, adjusting for clinical and demographic characteristics. Cohort indicators for year that the enrollee met study criteria were included to account for cohort effects.
Averaging over all cohorts and quarters, compared with whites, blacks had lower odds of filling any antimanic and mood stabilizer prescriptions specifically (40%-49% and 47%-63%, respectively), but similar odds of filling prescriptions for antipsychotic monotherapy. After Bonferroni adjustment, compared with whites, there were no statistically significant disparities for Hispanics in filling prescriptions for any, or specific antimanic medications.
Rates of antimanic medication use were low regardless of race/ethnicity. However, we found disparities in antimanic medication use for blacks compared with whites and these disparities persisted over time. We found no Hispanic-white disparities. Quality improvement efforts should focus on all individuals with bipolar disorder, but particular attention should be paid to understanding disparities in medication use for blacks.

9 Reads
  • Source
    • "The same applies with regard to mood stabilizers. A recent survey found longitudinal differences in antimanic medication use for blacks compared with whites [22]. However, significant absence of previous studies investigating mood stabilizers' prescribing does not allow comparison and thus generalization of findings in this field. "
    [Show abstract] [Hide abstract]
    ABSTRACT: No studies have been conducted in Greece with the aim of investigating the influence of ethnicity on the prescribing and treatment outcome of voluntarily admitted inpatients. Most studies conducted in the UK and the US, both on inpatients and outpatients, focus on the dosage of antipsychotics for schizophrenic patients and many suffer from significant methodological limitations. Using a simple design, we aimed to assess negative ethnic bias in psychotropic medication prescribing by comparing discrepancies in use between native and non-native psychiatric inpatients. We also aimed to compare differences in treatment outcome between the two groups. In this retrospective study, the prescribing of medication was compared between 90 Greek and 63 non-Greek inpatients which were consecutively admitted into the emergency department of a hospital covering Athens, the capital of Greece. Participants suferred from schizophrenia and other psychotic disorders. Overall, groups were compared with regard to 12 outcomes, six related to prescribing and six related to treatment outcome as assesed by standardised psychometric tools. No difference between the two ethnic groups was found in terms of improvement in treatment as measured by GAF and BPRS-E. Polypharmacy, use of first generation antipsychotics, second generation antipsychotics and use of mood stabilizers were not found to be associated with ethnicity. However, non-Greeks were less likely to receive SSRIs-SNRIs and more likely to receive benzodiazepines. Our study found limited evidence for ethnic bias. The stronger indication for racial bias was found in benzodiazepine prescribing. We discuss alternative explanations and give arguments calling for future research that will focus on disorders other than schizophrenia and studying non-inpatient populations.
    BMC Psychiatry 04/2011; 11(1):66. DOI:10.1186/1471-244X-11-66 · 2.21 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: Rising drug costs have increased focus on how new pharmaceuticals diffuse into the marketplace. The case of gabapentin use in bipolar disorder provides an opportunity to study the roles of marketing, clinical evidence, and prior authorization (PA) policy on off-label medication use. Observational study using Medicaid administrative and Verispan marketing data. We examined the association between marketing, clinical trials, and prior authorization on gabapentin use. Florida Medicaid, bipolar disorder-diagnosed enrollees ages 18 to 64 for fiscal years 1994 to 2004. Gabapentin prescriptions increased from 8/1000 enrollees per quarter in 1994 to a peak of 387/1000 enrollees in 2002. Its uptake tracked marketing efforts towards psychiatrists. The publication of 2 negative clinical trials in 2000 and the discontinuation of marketing expenditures towards psychiatrists were associated with an end to the steep rise in gabapentin prescriptions. After these events gabapentin use remained between 319/1000 and 387/1000 enrollees per quarter until the PA policy, which was associated with a 45% decrease in prescriptions filled. After 1 year, scientific evidence and marketing discontinuation were associated with a 5.4 percentage point decrease in the predicted probability of filling a gabapentin prescription and the PA policy, a 7.1 percentage point decrease. Pharmaceutical marketing can influence off-label medication prescribing, particularly when pharmacologic options are limited. Evidence of inefficacy and/or the cessation of pharmaceutical marketing, and a restrictive formulary policy can alter prescriber behavior away from targeted pharmacologic treatments. These results suggest that both information and policy are important means in altering physician prescribing behavior.
    Medical care 02/2010; 48(4):372-9. DOI:10.1097/MLR.0b013e3181ca404e · 3.23 Impact Factor
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Background: Pediatric bipolar disorder (BPD) is a debilitating recurrent chronic mental illness, characterized by cycling states of depression, mania, hypomania, and mixed episodes. Similarly to adults, children and adolescents with BPD are typically treated with pharmacotherapy and adjunctive psychotherapy. Nevertheless, emergency-room visits and hospitalizations are common for those suffering from pediatric BPD. Previous studies have shown declining trends in mean inpatient costs and length of stay (LOS) in the hospital for children with BPD. Aims: The objectives of this study were to calculate national estimates of the annual burden of inpatient hospitalizations of children and adolescents with BPD in the United States; to describe and compare the mean burden across various patient characteristics, hospital characteristics, and key comorbidities associated with BPD; and to determine the independent effects of these factors on hospitalization costs. Methods: Hospitalizations for children and adolescents whose primary diagnosis was BPD were selected from the Kids' Inpatient Database (KID) in 2003 and 2006. The burden for each year was estimated as total number of days in the hospital and total costs. Mean costs were calculated overall and for subpopulations identified by patient and hospital characteristics and by the top six comorbidities found for BPD. Ordinary-least-squares regression models explaining cost were estimated for both 2003 and 2006, and the models were compared by way of a Chow statistical test. Results: There were 39,136 (40,679) BPD in hospitalizations in 2003 (2006), with total associated costs of $176 ($233) million in 2003 (2006). The mean cost was $4,490 ($5,725), while the mean LOS was 8.12 (8.99) days in 2003 (2006). Factors associated with higher cost included youth (younger than 13), being black, being from a high-income family, having many diagnoses, being insured by Medicaid, living in the North East or West regions of the country, and having a long hospital stay. Post-traumatic stress disorder and oppositional defiant disorder were associated with higher costs in 2006. Discussion: Declining trends in mean cost and LOS, documented in previous studies for children with BPD, persisted into 2003 but showed a slight reversal by 2006. Over the three years, mean LOS rose by a little less than one day, while mean cost (not adjusted for inflation) rose by $1,235. Children and adolescents insured through Medicaid tended to stay in the hospital longer and have higher costs than those children who were privately insured. Implications for Health Policies: Due to relatively few expensive inpatient procedures for BPD patients, pediatric BPD hospitalizations, relative to hospitalizations overall, were significantly more burdensome on average in terms of days spent in the hospital than in terms of cost. To the extent that early detection of the disease along with appropriate outpatient treatment can be achieved, there could be significant reductions in the risk of hospitalizations for children with BPD. Implications for Further Research: Further studies should be conducted to determine if average LOS and mean hospitalization cost remain consistent with declining trends or whether the increase between 2003 and 2006 represents a trend reversal.
    Value in Health 05/2010; 13(3). DOI:10.1016/S1098-3015(10)72524-9 · 3.28 Impact Factor
Show more


9 Reads
Available from